Drug intelligence / Profile preview

naltrexone prodrug

Development stage
Unknown
Lead developer
Bristol Myers Squibb
Modality
Small Molecules
Administration
Intramuscular
01

Overview

Naltrexone prodrug is a small molecule therapeutic developed by Rusan Healthcare, specifically designed for the treatment of opioid and alcohol dependence. It serves as a precursor to naltrexone, a potent opioid receptor antagonist. By blocking mu-opioid receptors, the drug inhibits the reinforcing effects of opioids and reduces alcohol cravings, facilitating long-term abstinence. This prodrug formulation is typically engineered for long-term release, often as a depot injection, to overcome the compliance challenges associated with daily oral naltrexone therapy. It is currently approved for use in managing substance use disorders in specific jurisdictions.

Other names
naltrexone long-acting injectablenaltrexone depot
02

Targets

KOR (Kappa opioid receptor)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)

Beyond the preview

Go deeper on naltrexone prodrug.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on naltrexone prodrug.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call